D Vassilieff

Publications (6)27.76 Total impact

• Article: Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

  S Park, R Sapena, C Kelaidi, D Vassilieff, D Bordessoule, A Stamatoullas, S Cheze, O Beyne-Rauzy, N Vey, C Rose, A Guerci, Shanti Natarajan-Amé, Gérard Tertian, B Slama, P Fenaux, F Dreyfus
  [show abstract] [hide abstract]
  ABSTRACT: We evaluated the prognostic value of serum ferritin (SF) level at diagnosis in 318 newly diagnosed IPSS low and int 1 (lower) risk MDS patients included in the French MDS registry, who did not require RBC transfusions and had baseline SF level determination. Increased baseline SF level (>300 ng/ml) was correlated with male gender, more pronounced anaemia, and diagnosis of RARS but had no negative impact on progression to AML or survival.
  Leukemia research 07/2011; 35(11):1530-3. · 2.36 Impact Factor
• Article: Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.

  S Park, D Vassilieff, V Bardet, F Viguié, F Dreyfus
  Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 11/2010; 24(11):1960-2. · 8.30 Impact Factor
• Article: High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

  L Mannone, C Gardin, M C Quarre, J F Bernard, D Vassilieff, L Ades, S Park, S Vaultier, F Hamza, M O Beyne-rauzy, S Cheze, S Giraudier, P Agape, L Legros, L Voillat, F Dreyfus, P Fenaux
  [show abstract] [hide abstract]
  ABSTRACT: An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) with an endogenous erythropoietin (EPO) level <500 mU/ml. Most of the patients were classified as low or intermediate 1 according to the International Prognostic Scoring System. After 12 weeks, 44 (71%) patients had an erythroid response (34 major and 10 minor), including eight of 13 patients who were previous non-responders to conventional EPO. Two additional responses (one minor and one major) occurred, in 10 non-responders, after the addition of granulocyte colony-stimulating factor (G-CSF). Thirty-six of the 46 total responders (31/35 major and 5/11 minor) continued to respond on maintenance DAR after a median of 40 weeks (range 4-84). Median dose of DAR required to maintain response was 300 microg every 14 d. The only prognostic factors of favourable response were low endogenous EPO level and low or absent red blood cell transfusion requirement. Those results suggest that high-dose DAR alone yields high erythroid response rates in anaemia of lower risk MDS, possibly equivalent to those obtained with conventional EPO + G-CSF, although this will need to be confirmed in larger and randomised trials.
  British Journal of Haematology 07/2006; 133(5):513-9. · 4.94 Impact Factor
• Article: Pure red cell aplasia associated with myelodysplastic syndromes.

  S Park, A Merlat, M Guesnu, F Picard, F Viguié, D Vassilieff, F Dreyfus
  Leukemia 10/2000; 14(9):1709-10. · 9.56 Impact Factor
• Article: A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients with recurrent haemarthrosis.

  P Molho, P Verrier, N Stieltjes, J M Schacher, N Ounnoughène, D Vassilieff, C Menkes, Y Sultan
  [show abstract] [hide abstract]
  ABSTRACT: Between 1970 and 1994, 116 chemical and 90 radioactive synovectomies were performed in 107 patients with severe haemophilia and two with type 3 von Willebrand's disease. The products used were osmic acid (OA) in 100 cases, 90-Yttrium in 35 cases, 186-Rhenium in 48, 169-Erbium in two, hexacetonide triamcinolone in 16 and radioactive gold in five cases. The use of radioactive colloids is not allowed in France in patients under 15 years of age. Twenty-nine patients had more than one synovectomy per joint. All patients were evaluated for 6 months post-synovectomy, using both a clinical and a radiological score. Six months after synovectomy, a good or excellent result was obtained for 81% of the joints treated with isotopes, compared with 44% of those treated with OA, P<0.001. This superiority of isotopes over osmic acid was still observed after 6 months for the 89 joints that were re-evaluated, with follow-up ranging from 1 to 9 years. It was possible to calculate a radiological score in 84 cases. With OA the best results were from the joints with the lowest scores pre-synovectomy (<7). No correlation could be established between the clinical and the radiological scores, due to the small size of the sample. In summary: (1) chemical and radioactive synovectomy are simple and safe procedures for haemophilic arthropathy, (2) in our series, after 6 months the efficacy of isotopic synovectomy was greater than that of chemical synovectomy, and this benefit seems to persist after 6 months, and up to 9 years in the group of patients with longer-term follow-up.
  Haemophilia 03/1999; 5(2):115-23. · 2.60 Impact Factor
• Article: Nonsurgical synovectomy in the treatment of arthropathy in Von Willebrand's Disease.

  G Salis, P Molho, P Verrier, N Stieltjes, D Vassilieff, N Ounnoughène, J M Schacher, G Perpignano, Y Sultan, C J Menkès
  [show abstract] [hide abstract]
  ABSTRACT: Von Willebrand's disease is the most common inherited bleeding disorder, with an overall prevalence in the general population of 0.8% to 1.3%. Hemarthrosis occurs mainly in the severest forms of the disease (type III), with a frequency of 3.5% to 11%, and can cause severe arthropathy similar to that seen in hemophilia. We retrospectively reviewed our experience with nonsurgical synovectomy in the treatment of recurrent hemarthrosis with arthropathy in patients with von Willebrand's disease. Four of our six patients had type III disease and the remaining two had type II disease. The age range was 13 to 63 years. The frequency of hemarthrosis prior to synovectomy was one to four per month. One (n = 2) or both (n = 1) knees were treated in 4 cases, one (n = 1) or both (n = 1) ankles in 3 cases and an elbow in one case. We used yttrium 90 in a dose of 5 mCi for one knee, rhenium 186 in a dose of 2 mCi for two ankles and the elbow and osmic acid for two knees and one ankle. Clinical and radiological results were evaluated six months after synovectomy using the World Federation of Hemophilia score. Radiologic lesions remained stable and clinical manifestations improved in every case (p < 0.05). Five patients achieved a complete remission. Safety was satisfactory. The clinical efficacy of synovectomy done, using radiocolloids or osmic acid in arthropathy due to von Willebrand's disease, seems similar to that in hemophilia.
  Revue du rhumatisme (English ed.) 05/1998; 65(4):232-7.